Finance

Stocks making the biggest moves after hours: CSX, Knight-Swift Transportation and more

In this article

A CSX freight train is seen in Orlando.
Paul Hennessy | Lightrocket | Getty Images

Check out the companies making headlines in extended trading.

CSX — The transportation company’s shares were up 2.6% after the company’s first-quarter earnings and revenue topped analysts’ expectations. CSX posted earnings of 48 cents per share and revenue of $3.71 billion. Analysts polled by Refinitiv had anticipated earnings of 43 cents per share and $3.58 billion in revenue.

Knight-Swift Transportation — Shares fell less than 1% after the freight transportation company reported a miss on earnings for the first quarter. The company reported adjusted earnings of 73 cents per share, while analysts estimated per-share earnings of 81 cents, according to FactSet. However, the company’s revenue of $1.64 billion came above analysts’ expectations of $1.61 billion. Knight-Swift also cut its full-year EPS guidance for 2023.

W.R. Berkley — Shares of the commercial lines insurer slipped 2% after W.R. Berkley reported net premiums that were lower than analysts’ estimates, coming in at $2.49 billion versus expectations for $2.53 billion, according to FactSet. The company posted operating earnings-per share of $1.00, compared to $1.10 per share a year ago.

PPG Industries —The paint manufacturer’s stock gained less than 1%. The company issued second-quarter guidance that came in ahead of analysts’ expectations, according to FactSet. PPG anticipates adjusted earnings will be $2.05 to $2.15 per share, compared to analysts’ estimates of $1.96 per share. PPG also issued rosy guidance for the full year.

Products You May Like

Articles You May Like

Biden makes another push for tuition-free community college. Here’s why it may work this time
JetBlue shares tumble 14% after airline lowers 2024 revenue outlook
TSMC beats first-quarter revenue and profit expectations on strong AI chip demand
Most retirees don’t delay Social Security benefits, research finds. Here’s why experts say it pays to wait
Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up

Leave a Reply

Your email address will not be published. Required fields are marked *